Team
Benjamin Bunney, M.D.
Dr. Bunney earned his B.A. from New York University in 1960 and his M.D. from the NYU School of Medicine in 1964. He completed an internship and residency in Internal Medicine in the NYU Division of Bellevue Hospital. Dr. Bunney served as a Captain in the Air Force, practicing internal medicine for two years during the Vietnam War. He then went to Yale and completed a psychiatric residency. He served on the faculty of the Yale School of Medicine from 1971 to 2007 and was Chairman of the Department of Psychiatry from 1987 to 2007. In addition, he was a Professor in the departments of Pharmacology and Neurobiology and taught in both departments for many years. At present he is the Charles BG Murphy Professor Emeritus of Psychiatry. Dr. Bunney is one of the world’s leading experts on the brain’s dopamine systems whose malfunctioning has been implicated in the pathogenesis of Schizophrenia, substance abuse and neurological movement disorders such as Parkinson’s Disease. He is a past president of the American College of Neuropsychopharmacology and the recipient of its highest research award, the Daniel H. Efron Award. He was also the first recipient of the Lieber Prize for outstanding achievement in research on mental illness from the National Alliance for Research on Schizophrenia and Depression. Dr. Bunney was elected to membership in the Institute of Medicine, National Academy of Sciences in 1993. He has also served on numerous editorial boards, pharmaceutical companies’ Scientific Advisory Boards, and Boards of Directors. He is a co-founder of several start-up companies including Neurogen and PsychoGenics.
- Dr. Bunney on Linkedin
- Profile on Yale School of Medicine
- Dr. Bunney on Doximity
- Profile on U.S. News
- Dr. Benjamin Bunney’s Publications
Seth Feuerstein, M.D., J.D.
Dr. Feuerstein co-founded Elm Street Ventures in New Haven, Connecticut where he was a general partner and focused on early stage company investment, management and formation eventually leaving to have a direct role in companies as an entrepreneur and investor. His work includes the development, funding or founding of several companies including HistoRx (where he is on the Board of Directors), Carigent Therapeutics, Hadapt, ShareGrove (acquired by Facebook), Affomix (acquired by Illumina), NELS (a CRO) and Biorelix. After completing medical and law school at New York University he completed his clinical training in psychiatry at the Yale University School of Medicine in New Haven, CT where he remains on the clinical faculty. During his residency training he developed a fellowship to train clinicians in technology commercialization from academic centers and worked on intellectual property management, licensing and new venture development for Yale University. He is also involved in community activities including the founding of Little Wonder, Inc, a non-profit that works to improve the experience of patients undergoing cancer treatment.
Henry Jarecki, M.D.
Dr. Jarecki graduated from the University of Heidelberg Medical School in Germany in 1957. He did his psychiatric training at the Yale University School of Medicine where he is Professor of Psychiatry. In 1964 while practicing in New Haven and Teaching at Yale he wrote a textbook with Dr. Thomas Detre: Modern Psychiatric Treatment. In 1970, he left the practice of medicine to enter the bullion business, ultimately leading The Mocatta Group (TMG), the world’s largest gold and silver trading company and soon thereafter forming Brody White, a professional commodities brokerage company. In 1986 he sold TMG to his partners, Standard Chartered Bank of London, England; in 1995, he sold his brokerage company to Societe Generale, a French overseas bank. From 1989 to 1999, he was Chairman of Moviefone until it became a public company and thereafter was sold to America On-Line. In 2005, the Futures Industry of America inducted Dr. Jarecki into its Futures Hall of Fame. Since then, Dr. Jarecki has broadened his interest to investment management (which includes the development of asset allocation theory and practice within Gresham Investment Management LLC, a firm he founded and chairs that currently manages almost $7 billion), resort management (Guana Hotel Island, Norman Island and Hannah Bay in the British Virgin Islands) and biotechnology (Psychogenics, Inc., a 160-person drug research and discovery company in Tarrytown, NY).
Martin Major, J.D., L.L.M.
Mr. Major, who first worked as an attorney specializing in complex tax and business issues, subsequently left the practice of law and focused on operationally complex and diverse business enterprises as an advisor, investor and manager. He has had varied successful experiences ranging from the revitalization of world famous landmarks and destinations such as The Pike Place Market (in Seattle, Washington) to overseas telecommunications as well as complex real estate transactions including Icon a leader in the field of ownership and operational management in the parking industry. In addition to his role as an investor and manager he is a supporter of early stage technology projects, medical care and the arts through philanthropy as well.